ENOV

Enovis is an orthopedic med-tech mid-cap whose headline numbers look alarming but are dominated by non-cash, acquisition-driven charges. FY2025 revenue grew 6.7% to $2.25B with a strong and expanding 59.8% gross margin (gross profit +13.9%, outpacing revenue), yet the company reported a -$1.18B net loss and -50% operating margin. The reconciliation is the key: depreciation & amortization ran $1.34B (+44.9% YoY) — exceeding the entire operating loss — reflecting amortization and likely impairment of intangibles from the January 2024 Lima acquisition. Operating cash flow tells a healthier story, nearly doubling to $217M (+91.4%); against $197M of capex, free cash flow is roughly breakeven-to-slightly-positive. So this is not a cash-incinerating business, but its GAAP earnings power is buried under deal accounting and the cash conversion is thin.

The balance sheet is where the caution lies. Cash sat at just $36.4M (-24.5%) against $1.26B of long-term debt and a $35M current portion that jumped 74.8% — a slim liquidity buffer for a leveraged company (liabilities/equity 1.57x). Equity fell 41.9% as the accumulated deficit ballooned to -$1.47B, and the multi-year loss trail (positive $71.7M in 2021 to deepening losses every year since) shows the Lima integration has yet to translate scale into GAAP profit. Management's pivot is visible in the filing: the October 2025 Dr Comfort divestiture (up to $60M, $45M upfront) trims non-core P&R and brings in needed cash, while R&D up 31.8% funds the faster-growing Recon implant segment they tout as a market leader.